A Phase 3 interventional study of RMC-6236 and Gemcitabine in Pancreatic Cancer, PDAC and PDAC - Pancreatic Ductal Adenocarcinoma, sponsored by Revolution Medicines, Inc.. Active, not recruiting at 60 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-02.
Sponsored by Revolution Medicines, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Pancreatic Neoplasms by Revolution Medicines, Inc. — 9 open to participants now, 11 under way, 5 of them phase 3. Pancreatic Neoplasms · Revolution Medicines, Inc..
Among the 13 studies in Pancreatic Neoplasms by Revolution Medicines, Inc., this one is the 8th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2024, is one of 5 in phase 3, reaches primary completion later than 0 of the 10 other live ones, and was the 7th registered.
3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.
Browse Pancreatic Neoplasms studies →9 of the 13 studies in Pancreatic Neoplasms by Revolution Medicines, Inc. are open now, in 12 countries. Recruiting first, the newest first:
Revolution Medicines, Inc. · Sites in United States
Ages 18+
Revolution Medicines, Inc. · Sites in United States, Austria, Italy and 2 more countries
Ages 18+
Revolution Medicines, Inc. · Sites in United States, Australia, Austria and 18 more countries
Ages 18+
Revolution Medicines, Inc. · Sites in United States
Ages 18+
Revolution Medicines, Inc. · Sites in United States, Canada, France and 7 more countries
Ages 18+
By country, each count listing its studies:
Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 4 · Phase 3 5
First in 2019; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 500 is above the median of 47 across 2,932 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 554 across the 12 interventional studies. Of the 1 that completed or were terminated, 1 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
Revolution Medicines, Inc. is the lead sponsor of 20 studies on the registry; 13 are open to participants now.
3 of the studies in Pancreatic Neoplasms by Revolution Medicines, Inc. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06040541Revolution Medicines, Inc.Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | 2026-12-31 |
| NCT05462717Revolution Medicines, Inc.Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | 2027-03-31 |
| NCT05379985Revolution Medicines, Inc.Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | 2027-05-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 13 studies in Pancreatic Neoplasms by Revolution Medicines, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.
This is a global, randomized, open-label, Phase 3 study designed to evaluate whether treatment with RMC-6236 will improve progression free survival (PFS) or overall survival (OS) compared to Investigator's choice of standard of care chemotherapy in patients with metastatic PDAC who were previously treated with one prior line of therapy with 5-fluorouracil (5-FU) based or gemcitabine-based regimen.
Patients will be randomized in a 1:1 ratio to receive RMC-6236 (Arm A) or Investigator's choice of standard of care chemotherapy (Arm B).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study drug
Drug: RMC-6236
Patients randomized to Investigator's choice of standard of care chemotherapy will receive one of the following four treatments: * Gemcitabine and nab-paclitaxel (GnP) * Oxaliplatin, leucovorin, irinotecan, and 5-FU (Modified FOLFIRINOX: mFOLFIRINOX) * Liposomal irinotecan (Nal-IRI + 5-FU/LV) * Oxaliplatin, leucovorin and 5-FU IV (FOLFOX)
Drug: Gemcitabine · Drug: nab-paclitaxel · Drug: Irinotecan · Drug: Liposomal irinotecan · Drug: 5-fluorouracil · Drug: leucovorin · Drug: Oxaliplatin
Oral Tablets
intravenous (IV) infusion
IV infusion
IV infusion
IV infusion
IV infusion
IV infusion
IV infusion
Progression free survival (PFS) in the RAS G12-mutant population
PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is per response evaluation criteria in solid tumors (RECIST) v1.1 and as assessed by blinded independent central review (BICR)
Time frame: Up to approximately 3 years
Overall survival (OS) in the RAS G12-mutant population
OS is defined as the time from randomization until death from any cause.
Time frame: Up to approximately 3 years
PFS in the all-patient population
PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is per RECIST v1.1 and as assessed by BICR.
Time frame: Up to approximately 3 years
OS in the all-patient population
OS is defined as the time from randomization until death from any cause.
Time frame: Up to approximately 3 years
Objective response in the RAS G12 and all-patient populations
Objective response is defined as partial response (PR) or completed response (CR) per RECIST v1.1, assessed by BICR.
Time frame: Up to approximately 3 years
Time to deterioration (TTD) in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Pancreatic Cancer Module (EORTC QLQ-PAN26) in the RAS G12 and all-patient populations
TTD is defined as the time from randomization to the first occurrence of deterioration as defined by a change of at least 10 points, or death, whichever occurs first, in each subscale in EORTC QLQ-PAN26.
Time frame: Up to approximately 3 years
Time to deterioration (TTD) in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in the RAS G12 and all-patient populations
TTD is defined as the time from randomization to the first occurrence of deterioration as defined by a change of at least 10 points, or death, whichever occurs first, in each subscale and global QoL score in EORTC QLQ-C30.
Time frame: Up to approximately 3 years
Objective response per investigator in RAS G12 and all- patient populations
Objective response is defined as PR or CR per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, as assessed by the investigator.
Time frame: Up to approximately 3 years
Duration of response (DOR) in RAS G12 and all-patient populations
DOR is defined as time from first evidence of objective response (PR or CR) to disease progression or death due to any cause, whichever occurs first, as assessed by BICR and by the investigator.
Time frame: Up to approximately 3 years
Time to response (TTR) in RAS G12 and all-patient populations
TTR is defined as time from randomization to first evidence of objective response (PR or CR), as assessed by BICR and by the investigator.
Time frame: Up to approximately 3 years
Percentage of patients with adverse events (AEs)
Time frame: Up to approximately 3 years
Pharmacokinetics of RMC-6236 in RAS G12 and all-patient populations
Pharmacokinetics are defined by blood concentrations of RMC-6236 over time.
Time frame: Up to approximately 3 years
Started Oct 2024 (actual). Primary completion is estimated for Jun 2026, 20 months after the start.
Of 84 phase 3 interventional studies under Pancreatic Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 77. This study's planned 20 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Daraxonrasib